<DOC>
	<DOCNO>NCT00802867</DOCNO>
	<brief_summary>Objectives : - To present rate adverse reaction dose DAPTACEL® vaccine administer child 4 6 year age previously receive four dos PENTACEL™ vaccine . - To present immunogenicity single dose DAPTACEL® vaccine administer child 4 6 year age previously receive four dos PENTACEL™ vaccine .</brief_summary>
	<brief_title>Study DAPTACEL® Administered 5th Dose 4 6-Year-Old Children Previously Immunized With PENTACEL™</brief_title>
	<detailed_description>This study design assess safety immunogenicity DAPTACEL® vaccine administer 4 6 year age accord US standard care . The study population consist PENTACEL™-primed subject Aventis Pasteur 's pivotal study 494-01 494-03 . These child receive DAPTACEL® vaccine 5th dose immunization 4 6 year age .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<criteria>Inclusion Criteria : Aged ≥ 4 year 6 year . Signed date Investigational Review Boardapproved inform consent parent legally authorize representative . Judged good health basis report medical history physical examination . Able willing attend schedule visit comply study procedure . Has document complete infant series 4th dose Study 49401 Study 49403 , consist four previous administration PENTACEL™ . Exclusion Criteria : Received 5th dose DTaPcontaining vaccine schedule 4 6 year age . Serious underlie chronic disease , include , limited : Diabetes mellitus ; malignancy ; cardiopulmonary disease ; renal , endocrinologic , hepatic dysfunction ; hematologic disorder ; Unstable evolve neurologic disorder may predispose subject seizure neurologic deterioration . Known suspected primary acquire disease immune system . Administration immune globulin blood product within last 3 month , injected oral corticosteroid immunomodulatory therapy within 6 week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial long receive 1 course within last 2 week prior enrollment . Had allergy shot start change regimen dose allergy shot within last 4 week . Receipt vaccine within past 30 day , plan receive another vaccine within 30 day Visit 2 blood draw , exclusion MMR®II IPV . Any condition , opinion Investigator , would pose health risk subject interfere evaluation vaccine . Enrolled another vaccine trial . Personal history physiciandiagnosed laboratoryconfirmed pertussis disease within past 30 month . Known suspect allergy vaccine vaccine component intend use study . Temporary contraindication : A subject meet either follow criterion time plan vaccination enrollment defer complete resolution symptom : Oral temperature ≥ 100.4°F ( ≥ 38.0ºC ) ( Note : A tympanic thermometer use ) . Any moderate severe acute illness without fever .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>DAPTACEL®</keyword>
	<keyword>PENTACEL™</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
</DOC>